Syndax Readies FDA Filing In Leukemia After Stopping Revumenib Trial Early For Efficacy

 
• By Alaric DeArment
  
Syndax announced results of the Phase I/II AUGMENT-101 trial of revumenib in acute leukemias • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D